Xuanzhu Biopharmaceutical Co., Ltd. (2575.HK)
HKSE · HKD · Healthcare · Drug Manufacturers - Specialty & Generic
HK$8.51 (+0.35%) as of
Key statistics
- Market cap
- 4.41B
- EPS (TTM)
- -0.530
- Dividend yield
- 0.00%
- 52-week range
- 8.005 – 96.900
- Revenue (TTM)
- 103.32M
- Profit margin
- -203.19%
- Volume
- 2.43M
About Xuanzhu Biopharmaceutical Co., Ltd.
Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates include Core- KBP-3571 for the treatment of duodenal ulcer, adult reflux esophagitis, pylori eradication; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer, R+/HER2- locally advanced or metastatic breast cancer, and adjuvant therapy for HR+/HER2- early breast cancer; and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase positive advanced non-small-cell lung cancer, post-operative adjuvant therapy for patients with ALK-positive non-small cell lung cancer. The company also develops KM501, a first-in-class HER2/HER2 bispecific antibody drug conjugate, which is in Phase I clinical trial; KM602, which is in Phase I clinical trial for anti-tumor; XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 inhibitor; and XZP-6924, a ubiquitin-specific protease 1 (USP1) inhibitor. In addition, it develops XZB-0004, an oral small molecule anexelekto inhibitor; XZP-6877, a DNA-dependent protein kinase inhibitor; NG-350A, a clinical-stage intravenously administered oncolytic immunotherapy therapy; XZP-5610, a non-steroid farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Xuanzhu Biopharmaceutical Co., Ltd. was founded in 2008 and is headquartered in Beijing, China. Xuanzhu Biopharmaceutical Co., Ltd. is a former subsidiary of Sihuan Pharmaceutical Holdings Group Ltd.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Beijing, China
- Employees
- 344
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.